Skip to main content
Free access
Renal Cell Cancer
February 10, 2012

Outcomes of “real world” treatment for metastatic renal cell carcinoma (mRCC).

Abstract

406
Background: Targeted therapies have expanded treatment options for mRCC. Using a joint community/academic center database, we determined outcomes for “real world” mRCC patients (pts) in order to understand current treatment patterns and their effectiveness.
Methods: A retrospective cohort dataset included all identified adult mRCC pts receiving care in Duke University Health System and 11 community oncology practices, diagnosed and alive since Jan. 2007, and not enrolled in a trial. Standardized chart abstraction supplemented the electronic medical record. Demographics, comorbidities, tumor characteristics, treatment patterns and outcomes were recorded. Pts were grouped by exposure sequence (TKI [sorafenib, sunitinib or pazopanib], mTOR [temsirolimus or everolimus], TKI/mTOR, etc.) for 9 sequences. Outcomes analysis for overall survival (OS) included Cox regression.
Results: The cohort included 385 pts, 64 yrs old (±10.1), 66% male, 72% Caucasian; 64% had clear cell histology (25% unknown). Median OS was: mTOR (N=33; 5.4 mo), mTOR/TKI (N=11; 9.3 mo), TKI/mTOR (N=33; 13.7 mo), TKI (N=108; 21.1 mo), TKI/mTOR/TKI (N=18; 29.8 mo), TKI/TKI/mTOR (N=11; 33.1 mo), Other (N=40; 38.2 mo), TKI/TKI (N=32; 42.9 mo), No Therapy (N=99; not reached). “Other” pts received a combination or a non-TKI, non-mTOR monotherapy in the 1st three exposures. “No Therapy” pts had received no systemic therapy as of data analysis; most were alive and censored. Pts in the mTOR only sequence had trends toward worse disease at baseline with more metastatic sites (median 2.0; p=.067) and impaired performance status (18%; p=NS). When significant covariates were controlled, OS (vs. No Therapy) was poorest for pts receiving mTOR only (Hazard Ratio[HR]=2.3) and best for pts receiving TKI/TKI (HR=0.50). Significant risks were evident with liver metastasis (HR=1.7) and impaired performance status (HR=3.1).
Conclusions: In the real world setting pts receiving mTOR as the 1st treatment exposure had worse OS, likely because pts with more aggressive disease were preferentially treated with mTOR. Outcomes were consistent with contemporary trials; however, several sequences (e.g. TKI/TKI, No Therapy) had surprisingly long OS, which requires further evaluation.

Information & Authors

Information

Published In

Journal of Clinical Oncology
Pages: 406
PubMed: 28143108

History

Published online: February 10, 2012
Published in print: February 10, 2012

Permissions

Request permissions for this article.

Authors

Affiliations

Michael Roger Harrison
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Daniel J. George
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Mark S. Walker
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Lori L. Hudson
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Connie Chen
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Beata Korytowsky
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Edward J. Stepanski
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY
Amy P. Abernethy
Duke Cancer Institute, Durham, NC; ACORN Research, Memphis, TN; Pfizer Inc., New York, NY

Metrics & Citations

Metrics

Altmetric

Citations

Article Citation

Download Citation

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Michael Roger Harrison, Daniel J. George, Mark S. Walker, Lori L. Hudson, Connie Chen, Beata Korytowsky, Edward J. Stepanski, Amy P. Abernethy
Journal of Clinical Oncology 2012 30:5_suppl, 406-406

View Options

View options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

Purchase this article to get full access to it.

Purchase this Article

Subscribe

Subscribe to this Journal
Renew Your Subscription
Become a Member

Media

Figures

Other

Tables

Share

Share

Share article link

Share